Key facts
- It has raised $133.9M; the latest was Later Stage VC ($83.9M) in Sep 2024.
- Notable investors include Old College Capital, Syncona, The University of Edinburgh.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Resolution Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Resolution Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Resolution Therapeutics
Developer of cell therapies designed to aid in the treatment of end-stage liver diseases. The company's services include investigating the use of macrophages as therapeutic agents to treat liver cirrhosis and other ailments, enabling the medical community to address the unmet regenerative therapeutic needs related to chronic liver diseases.
- Sector
- Healthcare
- HQ
- Edinburgh, United Kingdom
- Founded
- 2017
- Employees
- 74
- Website
- resolution-tx.com/
- Ownership
- Privately Held (backing)
Resolution Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Resolution Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Resolution Therapeutics in its N-PORT filings yet. We sweep new filings monthly.